Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlookJul 29Quarterly updatedeutetrabenazinefremanezumab-vfrm
FDA approves labeling supplement for Actavis's orally disintegrating risperidone tabletsJul 1Regulatory decisionrisperidoneTeva Pharmaceutical Industries Ltd
Sign inSign in